Previous Close | 2.3300 |
Open | 2.1700 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 2.1700 - 2.1700 |
52 Week Range | 1.1600 - 3.5600 |
Volume | 150 |
Avg. Volume | 0 |
Market Cap | N/A |
Beta (3Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The St. Laurent, Quebec-based company said it had a loss of 5 cents per share. The biopharmaceutical company posted revenue of $40,000 in the period. In the final minutes of trading on Tuesday, the company's ...
On a per-share basis, the St. Laurent, Quebec-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $88,000 in the period. In the final minutes of trading on Monday, ...
In this article, I’m going to take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...